Imatinib mesylate as add-on therapy for pulmonary arterial hypertension

Results of the randomized IMPRES study

Marius M. Hoeper, Robyn J. Barst, Robert C. Bourge, Jeremy Feldman, Adaani E. Frost, Nazzareno Galié, Miguel Angel Gómez-Sánchez, Friedrich Grimminger, Ekkehard Grünig, Paul M Hassoun, Nicholas W. Morrell, Andrew J. Peacock, Toru Satoh, Gérald Simonneau, Victor F. Tapson, Fernando Torres, David Lawrence, Deborah A. Quinn, Hossein Ardeschir Ghofrani

Research output: Contribution to journalArticle

Abstract

Background-: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results-: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm-5 symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm-5 (95% confidence interval,-502 to-255; P

Original languageEnglish (US)
Pages (from-to)1128-1138
Number of pages11
JournalCirculation
Volume127
Issue number10
DOIs
StatePublished - Mar 12 2013

Fingerprint

Pulmonary Hypertension
Vascular Resistance
Therapeutics
Placebos
Confidence Intervals
Brain Natriuretic Peptide
Platelet-Derived Growth Factor
Imatinib Mesylate
Hemodynamics
Serum

Keywords

  • drugs
  • exercise
  • hemodynamics
  • hypertension
  • pulmonary

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., ... Ghofrani, H. A. (2013). Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation, 127(10), 1128-1138. https://doi.org/10.1161/CIRCULATIONAHA.112.000765

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension : Results of the randomized IMPRES study. / Hoeper, Marius M.; Barst, Robyn J.; Bourge, Robert C.; Feldman, Jeremy; Frost, Adaani E.; Galié, Nazzareno; Gómez-Sánchez, Miguel Angel; Grimminger, Friedrich; Grünig, Ekkehard; Hassoun, Paul M; Morrell, Nicholas W.; Peacock, Andrew J.; Satoh, Toru; Simonneau, Gérald; Tapson, Victor F.; Torres, Fernando; Lawrence, David; Quinn, Deborah A.; Ghofrani, Hossein Ardeschir.

In: Circulation, Vol. 127, No. 10, 12.03.2013, p. 1128-1138.

Research output: Contribution to journalArticle

Hoeper, MM, Barst, RJ, Bourge, RC, Feldman, J, Frost, AE, Galié, N, Gómez-Sánchez, MA, Grimminger, F, Grünig, E, Hassoun, PM, Morrell, NW, Peacock, AJ, Satoh, T, Simonneau, G, Tapson, VF, Torres, F, Lawrence, D, Quinn, DA & Ghofrani, HA 2013, 'Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study', Circulation, vol. 127, no. 10, pp. 1128-1138. https://doi.org/10.1161/CIRCULATIONAHA.112.000765
Hoeper, Marius M. ; Barst, Robyn J. ; Bourge, Robert C. ; Feldman, Jeremy ; Frost, Adaani E. ; Galié, Nazzareno ; Gómez-Sánchez, Miguel Angel ; Grimminger, Friedrich ; Grünig, Ekkehard ; Hassoun, Paul M ; Morrell, Nicholas W. ; Peacock, Andrew J. ; Satoh, Toru ; Simonneau, Gérald ; Tapson, Victor F. ; Torres, Fernando ; Lawrence, David ; Quinn, Deborah A. ; Ghofrani, Hossein Ardeschir. / Imatinib mesylate as add-on therapy for pulmonary arterial hypertension : Results of the randomized IMPRES study. In: Circulation. 2013 ; Vol. 127, No. 10. pp. 1128-1138.
@article{8c48b5397e1f448b99555782977629e4,
title = "Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study",
abstract = "Background-: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results-: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm-5 symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41{\%} patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95{\%} confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm-5 (95{\%} confidence interval,-502 to-255; P",
keywords = "drugs, exercise, hemodynamics, hypertension, pulmonary",
author = "Hoeper, {Marius M.} and Barst, {Robyn J.} and Bourge, {Robert C.} and Jeremy Feldman and Frost, {Adaani E.} and Nazzareno Gali{\'e} and G{\'o}mez-S{\'a}nchez, {Miguel Angel} and Friedrich Grimminger and Ekkehard Gr{\"u}nig and Hassoun, {Paul M} and Morrell, {Nicholas W.} and Peacock, {Andrew J.} and Toru Satoh and G{\'e}rald Simonneau and Tapson, {Victor F.} and Fernando Torres and David Lawrence and Quinn, {Deborah A.} and Ghofrani, {Hossein Ardeschir}",
year = "2013",
month = "3",
day = "12",
doi = "10.1161/CIRCULATIONAHA.112.000765",
language = "English (US)",
volume = "127",
pages = "1128--1138",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Imatinib mesylate as add-on therapy for pulmonary arterial hypertension

T2 - Results of the randomized IMPRES study

AU - Hoeper, Marius M.

AU - Barst, Robyn J.

AU - Bourge, Robert C.

AU - Feldman, Jeremy

AU - Frost, Adaani E.

AU - Galié, Nazzareno

AU - Gómez-Sánchez, Miguel Angel

AU - Grimminger, Friedrich

AU - Grünig, Ekkehard

AU - Hassoun, Paul M

AU - Morrell, Nicholas W.

AU - Peacock, Andrew J.

AU - Satoh, Toru

AU - Simonneau, Gérald

AU - Tapson, Victor F.

AU - Torres, Fernando

AU - Lawrence, David

AU - Quinn, Deborah A.

AU - Ghofrani, Hossein Ardeschir

PY - 2013/3/12

Y1 - 2013/3/12

N2 - Background-: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results-: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm-5 symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm-5 (95% confidence interval,-502 to-255; P

AB - Background-: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results-: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm-5 symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm-5 (95% confidence interval,-502 to-255; P

KW - drugs

KW - exercise

KW - hemodynamics

KW - hypertension

KW - pulmonary

UR - http://www.scopus.com/inward/record.url?scp=84874948946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874948946&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.112.000765

DO - 10.1161/CIRCULATIONAHA.112.000765

M3 - Article

VL - 127

SP - 1128

EP - 1138

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 10

ER -